Vericel (VCEL) Notes Payables (2013 - 2014)
Vericel recorded quarterly Notes Payables of $2.5 million in Q2 2014, up 41566.67% quarter-over-quarter from $6000.0 in Q4 2013.
Vericel's Notes Payables history runs 2 years deep, the most recent figure standing at $2.5 million for Q2 2014.
- In Q2 2014, Notes Payables changed N/A year-over-year to $2.5 million; the TTM figure through Jun 2014 stood at $2.5 million (changed N/A YoY), while the FY2013 annual figure was $6000.0, changed N/A from the prior year.
- Notes Payables came in at $2.5 million for Q2 2014 at Vericel, up from $6000.0 in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $2.5 million in Q2 2014 to a low of $6000.0 in Q4 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Vericel | 1.69 Bn | 1.55 Bn | 49.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2014 | 2.50 Mn |
| Dec 31, 2013 | 6,000.00 |